Leonard G. Gomella, MD, FACS, presented “Prostate Cancer Management Decisions From Germline and Somatic Testing” during the 35th International Prostate Cancer Update conference on February 11, 2025, in Vail, Colorado.
This content is available free to the GRU Community. Login or create an account to view it.
How to cite: Gomella, LG. Prostate Cancer Management Decisions From Germline and Somatic Testing. February 11, 2025. Accessed Oct 2026. https://grandroundsinurology.com/prostate-cancer-management-decisions-from-germline-and-somatic-testing/
Prostate Cancer Management Decisions From Germline and Somatic Testing – Summary
Leonard G. Gomella, MD, FACS, Bernard W. Godwin, Jr. Professor of Prostate Cancer and Chairman of the Department of Urology, Thomas Jefferson University, Philadelphia, Pennsylvania, explores the role of germline and somatic testing in guiding prostate cancer management decisions. In this 16-minute presentation, Dr. Gomella shares that germline mutations elevate the risk of developing prostate cancer, influencing prognosis.
Somatic mutations, arising within tumors, are increasingly used to guide therapeutic decisions.
Dr. Gomella highlights the importance of somatic testing in identifying actionable mutations for targeted therapies such as PARP inhibitors and pembrolizumab. He emphasizes the HRR pathway’s role in DNA repair. Genetic testing is essential for patients with newly diagnosed metastatic castration-resistant prostate cancer, as recommended by multiple clinical guidelines.
Dr. Gomella underscores the need for precision medicine strategies incorporating genomic insights to personalize treatment. He also highlights the utility of liquid biopsies in identifying mutations noninvasively, minimizing the need for repeat tissue biopsies. He advocates for involving genetic counselors to manage complex results.
ABOUT THE AUTHOR
Leonard G. Gomella, MD, FACS, serves as the Bernard W. Godwin, Jr. Professor of Prostate Cancer, Chairman of the Department of Urology, Senior Director of Clinical Affairs for the Sidney Kimmel Comprehensive Cancer Center, and the Enterprise Vice President of Urology at the Jefferson Health System at Thomas Jefferson University in Philadelphia, Pennsylvania. Dr. Gomella's lab, a part of the Jefferson Sidney's Kimmel Comprehensive Cancer Center, is involved in clinical research for the development of techniques to treat cancers.
